Mario Alberto Accardi - 16 Sep 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
President, Orexin Program
Signature
/s/ Raphael Deferiere, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
16 Sep 2025
Net transactions value
-$174,846
Form type
4
Filing time
16 Sep 2025, 18:16:56 UTC
Previous filing
11 Sep 2025
Next filing
27 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Accardi Mario Alberto President, Orexin Program C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM /s/ Raphael Deferiere, attorney-in-fact 16 Sep 2025 0002074392

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Sale $158,506 -7,430 -3.6% $21.33 198,136 16 Sep 2025 Direct F1, F2, F3
transaction CNTA Ordinary Shares Sale $16,340 -742 -0.37% $22.02 197,394 16 Sep 2025 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.01 to $22.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.